Questcor to Report Second Quarter Financial Results on July 30, 2013
ANAHEIM, Calif., July 12, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release second quarter 2013 financial results on Tuesday, July 30, 2013 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, July 30, 2013 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments.. The call can be accessed in the following ways: -- By webcast: At Questcor's investor relations website,
ir.questcor.com.
-- By telephone: For both "listen-only" participants and those participants
who wish to take part in the question-and-answer portion of the call, the
dial-in number in the U.S. is (877) 354-0215. For participants outside
the U.S., the dial-in number is (253) 237-1173.
-- By audio replay: A replay of the conference call will be available for
seven business days following conclusion of the live call. The telephone
dial-in number for U.S. participants is (855) 859-2056. For participants
outside the U.S., the replay dial-in number is (404) 537-3406. The replay
access code for all callers is 16591264. About Questcor Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intent to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis. The FDA approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases". Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen(R) (tetracosactide) and Synacthen Depot(R), and has licensed the right to develop and seek FDA approval for these products in the United States. For more information about Questcor, please visit www.questcor.com. SOURCE Questcor Pharmaceuticals, Inc. /CONTACT: EVC Group. Gregory Gin, 646-445-4801, or Patty Eisenhaur, 951-316-0577; or Janine McCargo, 646-688-0425 /Web site: questcor.com |
